NewcelX Ltd: A New Era in Biotechnology
Following the completion of a significant merger, the newly formed company, NewcelX Ltd., is poised to make a remarkable impact in the biotechnology sector. This strategic combination involves NLS Pharmaceutics Ltd. and Kadimastem Ltd., now unified under the NewcelX name. Trading on the Nasdaq Capital Market is set to begin shortly, reflecting the ambition of this newly established entity.
Merger Details and Aftermath
The merger was finalized after thorough discussions and effective planning, in alignment with the agreed terms outlined in the Merger Agreement, which played a pivotal role in this transition. As of October 30, 2025, NewcelX will serve as the public face in the biotechnology arena, with a new ticker symbol, "NCEL", set to debut on October 31, 2025. The legacy of both original companies will now evolve into a powerful entity focused on advancing healthcare solutions.
Stock Exchange Transition
With the change of the ticker symbol to NCEL, stakeholders can expect a robust positioning on the Nasdaq. Furthermore, all existing warrants of NewcelX will be delisted from trading, simplifying the trading environment for investors. This consolidation streams all interests under one banner, enhancing clarity for market participants.
Significant Exchange Ratios and Share Structures
In an important financial maneuver, shareholders of Kadimastem received 0.706 shares of NewcelX for every Kadimastem share they possessed. This exchange ratio was carefully calculated to align with the reverse share split, effectively balancing the equity landscape for the unified company. Post-merger, NewcelX will have around 4.5 million common shares in circulation, along with preferred shares to support growth and investor interest.
Future Opportunities for Shareholders
In addition to the immediate share exchange benefits, existing shareholders will be privy to contingent value rights related to potential future financial returns from certain legacy assets under the NewcelX umbrella. This opens up opportunities for long-term value generation for investors who choose to be part of NewcelX's journey.
Leadership Perspectives and Vision
At the helm of this innovative biotech journey is Ronen Twito, the Executive Chairman and CEO of NewcelX. He emphasizes the groundbreaking nature of this merger, stating, "The completion of the merger and commencement of trading signifies a new chapter where exceptional science meets transformative solutions. We are excited to advance our clinical trials aiming at conditions like ALS and Type 1 diabetes, promising better outcomes without lifelong dependency on immunosuppression."
Scientific Innovation as the Driving Force
Prof. Michel Revel, the Chief Scientific Officer, shares similar enthusiasm, highlighting the merger as a pathway to realizing critical advancements in regenerative medicine. NewcelX’s focus on conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 diabetes places it at the forefront of innovative treatment methodologies, a direction that is both restorative and groundbreaking.
About the NewcelX Company
NewcelX Ltd. embodies a synthesis of cutting-edge cell-based therapies directed at neurodegenerative and metabolic disorders. Their approach merges state-of-the-art stem cell technologies with deep neuroscience expertise. This alliance is aimed solely at offering breakthrough regenerative treatments, not only targeting ALS and Type 1 diabetes, but also expanding into other critical areas.
Global Operations and Strategic Locations
The headquarters of NewcelX is situated in Zurich, Switzerland, ensuring a strategic operational base for their research and development activities that also extend to Ness Ziona, Israel. With a diverse executive team bringing various expertise and perspectives, NewcelX is favorably positioned to capitalize on global biotechnology advancements.
Frequently Asked Questions
What is NewcelX Ltd.?
NewcelX is a biotechnology firm formed from the merger of NLS Pharmaceutics Ltd. and Kadimastem Ltd., focusing on regenerative medicine.
When will NewcelX start trading publicly?
NewcelX is expected to commence trading on the Nasdaq under the ticker symbol "NCEL" on October 31, 2025.
What is the significance of the merger?
The merger unites two pioneering companies to enhance research and treatment solutions in neurodegenerative diseases, streamlining resources and expertise.
What therapies is NewcelX pursuing?
NewcelX aims to advance therapies primarily targeting ALS and Type 1 diabetes, focusing on innovative, regenerative treatment options.
Who are the key executives of NewcelX?
Ronen Twito serves as the CEO, and Prof. Michel Revel is the Chief Scientific Officer, leading a strong team with diverse expertise in biotechnology.
